Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 9, 2012, Pages 1416-1427

  Knijnenburg, Sebastiaan L ^a,b   Jaspers, Monique W ^b   van der Pal, Helena J ^a   Meeteren, Antoinette Y Schouten van ^a   Bouts, Antonia H ^a   Lieverst, Jan A ^a   Bökenkamp, Arend ^c   Koning, Caro C E ^b   Oldenburger, Foppe ^b   Wilde, James C H ^d   van Leeuwen E , Flora ^e   Caron, Huib N ^a   Kremer, Leontien C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Pediatric Surgical Center   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY MASS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFANT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEWBORN; PRESCHOOL CHILD; RADIATION DOSE; SCHOOL CHILD;

ADOLESCENT; ADULT; ALBUMINURIA; AMBULATORY CARE FACILITIES; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; NEPHRECTOMY; NETHERLANDS; ODDS RATIO; PREVALENCE; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; YOUNG ADULT;

EID: 84866130237     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09620911     Document Type: Article

References (37)

1. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA; EUROCARE Working Group: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45: 992-1005, 2009
2. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, JaspersMW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, CaronHN, van Leeuwen FE: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 297: 2705-2715, 2007
3. Oeffinger KC, Nathan PC, Kremer LC: Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Pediatr Clin North Am 55: 251-273, 2008
4. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, HudsonMM, Meadows AT, Friedman DL, Marina N, HobbieW, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL; Childhood Cancer Survivor Study: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355: 1572-1582, 2006
5. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F: Long-term evaluation of Ifosfamiderelated nephrotoxicity in children. J Clin Oncol 27: 5350-5355, 2009
6. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System. Pediatr Blood Cancer 48: 447-452, 2007
7. Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G: Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39: 454-461, 1999
8. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD: Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer 54: 983-989, 2010
9. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD: Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. Eur J Cancer 45: 3213-3219, 2009
10. StöhrW, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer 48: 140-147, 2007
11. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, Rost M, Zintl F: Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40: 348-354, 2003
12. Frisk P, Bratteby LE, Carlson K, Lönnerholm G: Renal function after autologous bone marrow transplantation in children: A long-term prospective study. Bone Marrow Transplant 29: 129-136, 2002
13. Breitz H: Clinical aspects of radiation nephropathy. Cancer Biother Radiopharm 19: 359-362, 2004
14. Cozzi F, Schiavetti A, Morini F, Zani A, Gambino M, Donfrancesco C, Cozzi DA: Renal function adaptation in children with unilateral renal tumors treated with nephron sparing surgery or nephrectomy. J Urol 174: 1404-1408, 2005
15. JaspersMW, Caron H, Behrendt H, van den Bos C, Bakker P, Van Leeuwen FE: The development of a new information model for a pediatric cancer registry on late treatment sequelae in The Netherlands. Stud Health Technol Inform 77: 895-899, 2000
16. Zappitelli M, Joseph L, Gupta IR, Bell L, Paradis G: Validation of child serum creatinine-based prediction equations for glomerular filtration rate. Pediatr Nephrol 22: 272-281, 2007
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
18. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114[Suppl 4th Report]: 555-576, 2004
20. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 47: 316-323, 2000
21. Viet AL, van den Hof S, Elvers LH, Seidell JC, Otten F, van Veldhuizen H: Risk Factors and Health in The Netherlands: A Survey by Municipal Public; Annual Report 2000, National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 2002
22. Patzer L, Ringelmann F, Kentouche K, FuchsD, Zintl F, Brandis M, Zimmerhackl LB, Misselwitz J: Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant 27: 319-327, 2001
23. Skinner R, Cotterill SJ, Stevens MC; United Kingdom Children's Cancer Study Group: Risk factors for nephrotoxicity after ifosfamide treatment in children: AUKCCSG Late Effects Group study. Br J Cancer 82: 1636-1645, 2000
24. Skinner R, Pearson AD, Coulthard MG, Skillen AW, Hodson AW, Goldfinch ME, Gibb I, Craft AW: Assessment of chemotherapyassociated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28: 81-92, 1991
25. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis. Lancet 375: 2073-2081, 2010
26. BashirH, CromD, Metzger M, Mulcahey J, JonesD, HudsonMM: Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatr Blood Cancer 49: 867-869, 2007
27. Rossi R, Danzebrink S, Hillebrand D, Linnenbürger K, Ullrich K, Jürgens H: Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 22: 27-32, 1994
28. Kaste SC: Bone-mineral density deficits fromchildhood cancer and its therapy. Areviewof at-risk patient cohorts and available imaging methods. Pediatr Radiol 34: 373-378, quiz 443-444, 2004
29. Wasilewski-Masker K, Kaste SC, Hudson MM, Esiashvili N, Mattano LA, Meacham LR: Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature. Pediatrics 121: e705-e713, 2008
30. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, CrijnsHJ, VanGilstWH, De ZeeuwD, De Jong PE; Prevend Study Group: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249: 519-526, 2001
31. Mäkipernaa A, Koskimies O, Jääskeläinen J, Teppo AM, Siimes MA: Renal growth and function 11-28 years after treatment of Wilms' tumour. Eur J Pediatr 150: 444-447, 1991
32. Mancini AF, Rosito P, Salmi S, Rondelli R, Alvisi P, Leopardi G, Fortuzzi A, Bedei L, Tzolas AC, Neri L, Campieri C, Pasini A, Cicognani A, Paolucci G: Renal function in patients previously treated for Wilms tumor in infancy. Riv Ital Pediatr 22: 882-888, 1996
33. Cardous-Ubbink MC, Geenen MM, Schade KJ, Heinen RC, Caron HN, Kremer LC, Van Leeuwen FE: Hypertension in longterm survivors of childhood cancer: A nested case-control study. Eur J Cancer 46: 782-790, 2010
34. Haddy TB, Mosher RB, Reaman GH: Hypertension and prehypertension in long-termsurvivors of childhood and adolescent cancer. Pediatr Blood Cancer 49: 79-83, 2007
35. Pietilä S, Ala-Houhala M, Lenko HL, Harmoinen AP, Turjanmaa V, Mäkipernaa A: Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment. Pediatr Blood Cancer 44: 363-369, 2005
36. Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Mö ller K, Wigger M, Peruzzi L, MehlsO, Schaefer F; ESCAPE TrialGroup: Strict bloodpressure control and progression of renal failure in children. N Engl J Med 361: 1639-1650, 2009
37. World Health Organization: The World Health Report 2002: Reducing Risks, Promoting Healthy Life, Geneva, Switzerland, World Health Organization, 2002